Virtus LifeSci Biotech Products ETF (BBP)
Assets
$130.65M
Virtus
Fee
0.77%
a year
Yield
0.0%
NA
Components
65
top 10: 27%
Performance
The fund's own total return, a year on average over the longer periods; volatility is the yearly standard deviation of its returns.
This year
+32.1%
1 year
+41.8%
3 years
+29.0%
5 years
+15.6%
10 years
+12.6%
Volatility 17.4% over one year, 20.2% over three; Sharpe ratio over three years 1.13.
Largest components
| MRNAModerna Inc | 5.77% | Healthcare | |
| IOVAIovance Biotherapeutics Inc | 4.44% | Healthcare | |
| VSTMVerastem Inc | 2.74% | Healthcare | |
| OMEROmeros Corporation | 2.46% | Healthcare | |
| HALOHalozyme Therapeutics Inc | 2.34% | Healthcare | |
| XERSXeris Pharmaceuticals Inc | 2.03% | Healthcare | |
| KNSAKiniksa Pharmaceuticals Ltd | 1.98% | Healthcare | |
| BGNEBeiGene Ltd | 1.90% | Healthcare | |
| RIGLRigel Pharmaceuticals Inc | 1.84% | Healthcare | |
| ZLABZai Lab Ltd | 1.83% | Healthcare |
Sectors
Healthcare100.0%
Regions
North America97.2%
Asia Emerging1.7%
United Kingdom1.4%
Europe Developed1.3%
Asset classes
Stock US92.9%
Stock non-US4.6%
Cash0.3%
About the fund
- Issuer
- Virtus
- Since
- 2014-12-16
- Listed on
- NYSE ARCA
- ISIN
- US26923G2021
- Turnover
- 48% a year
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
From the market data provider's fund data, read 2026-10-19. Returns are the fund's own; past returns say nothing certain about future ones. None of this is advice.